Saeki Y - Search Results

1

B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells.

Chung RY, Saeki Y, Chiocca EA. Chung RY, et al. Among authors: saeki y. J Virol. 1999 Sep;73(9):7556-64. doi: 10.1128/JVI.73.9.7556-7564.1999. J Virol. 1999. PMID: 10438845 Free PMC article.

2

Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors.

Saeki Y, Ichikawa T, Saeki A, Chiocca EA, Tobler K, Ackermann M, Breakefield XO, Fraefel C. Saeki Y, et al. Among authors: saeki a. Hum Gene Ther. 1998 Dec 10;9(18):2787-94. doi: 10.1089/hum.1998.9.18-2787. Hum Gene Ther. 1998. PMID: 9874276

3

Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons.

Sena-Esteves M, Saeki Y, Camp SM, Chiocca EA, Breakefield XO. Sena-Esteves M, et al. Among authors: saeki y. J Virol. 1999 Dec;73(12):10426-39. doi: 10.1128/JVI.73.12.10426-10439.1999. J Virol. 1999. PMID: 10559361 Free PMC article.

4

MRI of transgene expression: correlation to therapeutic gene expression.

Ichikawa T, Högemann D, Saeki Y, Tyminski E, Terada K, Weissleder R, Chiocca EA, Basilion JP. Ichikawa T, et al. Among authors: saeki y. Neoplasia. 2002 Nov-Dec;4(6):523-30. doi: 10.1038/sj.neo.7900266. Neoplasia. 2002. PMID: 12407446 Free PMC article.

5

Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA.

Saeki Y, Breakefield XO, Chiocca EA. Saeki Y, et al. Methods Mol Med. 2003;76:51-60. doi: 10.1385/1-59259-304-6:51. Methods Mol Med. 2003. PMID: 12526158 No abstract available.

6

Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells.

Wade-Martins R, Saeki Y, Chiocca EA. Wade-Martins R, et al. Among authors: saeki y. Mol Ther. 2003 May;7(5 Pt 1):604-12. doi: 10.1016/s1525-0016(03)00060-1. Mol Ther. 2003. PMID: 12718903 Free article.

7

An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.

Kambara H, Okano H, Chiocca EA, Saeki Y. Kambara H, et al. Among authors: saeki y. Cancer Res. 2005 Apr 1;65(7):2832-9. doi: 10.1158/0008-5472.CAN-04-3227. Cancer Res. 2005. PMID: 15805284

8

Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.

Tyminski E, Leroy S, Terada K, Finkelstein DM, Hyatt JL, Danks MK, Potter PM, Saeki Y, Chiocca EA. Tyminski E, et al. Among authors: saeki y. Cancer Res. 2005 Aug 1;65(15):6850-7. doi: 10.1158/0008-5472.CAN-05-0154. Cancer Res. 2005. PMID: 16061668

9

Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.

Kambara H, Saeki Y, Chiocca EA. Kambara H, et al. Among authors: saeki y. Cancer Res. 2005 Dec 15;65(24):11255-8. doi: 10.1158/0008-5472.CAN-05-2278. Cancer Res. 2005. PMID: 16357128

10

Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene.

Suzuki M, Chiocca EA, Saeki Y. Suzuki M, et al. Among authors: saeki y. Mol Ther. 2007 Nov;15(11):2017-26. doi: 10.1038/sj.mt.6300273. Epub 2007 Jul 24. Mol Ther. 2007. PMID: 17653098 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

738 results

Search Page

Filters